Professor Dedee Murrell completed medical training at Cambridge and Oxford Universities, 3 years of internal medicine in the UK and USA, dermatology training at UNC-Chapel Hill, a fellowship in dermatopharmacology at Duke, blistering diseases and cell biology at New York University, and then became a clinical scholar at Rockefeller University. She holds a doctorate on the pathogenesis of blistering disorders, her main subspecialty interest, and her current research focusses on the development and validation of clinical outcome measures for autoimmune blistering diseases and epidermolysis bullosa to enable clinical trials to proceed in these orphan diseases. She has 418 peer reviewed papers, 16,7500 citations, an H index of 61, i!) of 213 and has edited 6 books, including the textbook, Blistering Diseases. She lectures at international congresses regularly and is a visiting professor in 5 continents. She was Congress President of the ICD 2021, the world’s first virtual Dermathon. She was founding Co-Editor of the International Journal of Women’s Dermatology and serves on the editorial boards of BJD, JAMA Dermatology, International Journal of Dermatology, JEADV, Acta Dermatovenereologica and JAAD International. She established Australia’s first dedicated dermatology clinical trial centre and is a KOL in trial design and conduct, serving on numerous advisory boards for more than 20 years. Her group established the ABQOL/TABQOL for measuring QOL in AIBD and she co-led the development and validation of the PDAI, BPDAI and MMPDAI. She established the Australasian Blistering Diseases Foundation in 2006.

William Damsky, MD, PhD is an Assistant Professor of Dermatology at Yale School of Medicine and board-certified dermatologist and dematopathologist. In clinical practice, he specializes in evaluation and treatment of patients with inflammatory skin disorders, especially cutaneous granulomatous diseases such as sarcoidosis and granuloma annulare. Dr. Damsky is interested in the identification and evaluation of new treatment approaches for inflammatory skin disease and conducts clinical trials in this area. As a physician-scientist with training in basic immunology, Dr. Damsky’s laboratory leverages the latest immunologic approaches to understand mechanisms of inflammatory skin disease and how they are affected by novel therapies. Dr. Damsky’s research has been supported by Career Development Awards from the Dermatology Foundation and the National Institute of Allergy and Infectious Diseases (NIAID). He was awarded the 2020 Young Investigator Award by the American Academy of Dermatology for his research in novel therapeutics for sarcoidosis.

Raj Chovatiya, MD, PhD, MSCI is Clinical Associate Professor of Medicine at Rosalind Franklin University Chicago Medical School and Founder and Director of the Center for Medical Dermatology + Immunology Research in Chicago, Illinois. His clinical and research focus includes the intersection of cutaneous immunology and inflammatory disease. He received his MD and PhD in immunology from Yale and completed his residency, postdoctoral research fellowship, and MS in Clinical Investigation at Northwestern University where he also served as Chief Resident. Dr. Chovatiya has a particular interest in optimizing patient-centered care, understanding chronic disease burden especially in understudied inflammatory diseases, exploring health and social disparities, and improving care across diverse skin types. He has published numerous abstracts and manuscripts and has been nationally and internationally recognized for his contributions as a clinician, educator, researcher, and leader.

Dr. David Rosmarin is the Chair of the Department of Dermatology at Indiana University and a clinical investigator. He previously served as Vice-Chair for Research and Education at Tufts Medical Center focusing on clinical trials for inflammatory disorders of the skin. For his training, Dr. Rosmarin went to medical school at NYU, dermatology residency at Boston University-Tufts Combined training program, and fellowship at Brigham and Women’s Hospital. Dr. Rosmarin joined Tufts Medical Center in 2013 focusing as a clinical trial investigator. In 2016, Dr. Rosmarin became the Director of the Clinical Trials Unit in the Department of Dermatology at Tufts Medical Center. Dr. Rosmarin’s studies have resulted in him becoming the PI for multicentered trials evaluating topical ruxolitinib in vitiligo, which has led to the first ever FDA indication for repigmenting vitiligo. Dr. Rosmarin is the first to use dupilumab for bullous pemphigoid which is now in a phase 3 program for an indication. Clinically Dr. Rosmarin is nationally recognized and serves as a referral for physicians with difficult to manage inflammatory diseases such as atopic dermatitis. Dr. Rosmarin educates medical students, residents, and research fellows. He served as Residency Program Director from 2016 to 2020 in which time he expanded the Tufts Medical Residency Program from nine positions to twelve residents and mentors faculty in education and research.